吸入布地奈德在治疗新生儿肺炎中的临床疗效

Clinical application of inhaled budesonide

目的探讨吸入布地奈德治疗新生儿肺炎的临床疗效。方法将160例新生儿肺炎患儿随机分为对照组与观察组,每组80例。2组患儿均接受常规治疗,对照组患儿接受氨溴索雾化吸入,观察组患儿接受氨溴索联合布地奈德吸入。比较2组临床疗效、症状体征改善时间及呼吸指标。结果观察组与对照组治疗有效率分别为93.8%和72.5%,差异有统计学意义(P<0.05);观察组患儿气促、鼻阻、口周紫绀、肺部罗音及住院时间显著少于对照组(P<0.05);治疗后24、48 h,观察组患儿二氧化碳分压(PCO2)显著下降,氧合指数(OI)显著上升,与对照组相比差异有统计学意义(P<0.05)。结论布地奈德联合氨溴索雾化吸入起效迅速,可显著缩短治疗时间,提高临床疗效。

Objective To explore the clinical effect of inhaled budesonide in treatment of neonatal pneumonia. Methods A total of 160 neonates with pneumonia were randomly divided into control group and experiment group with 80 in each group. All the patients received routine treat- ment. The control group was given ambroxol therapy, and the experiment group received inhaled budesonide. Clinical effect, recovery of main symptoms and signs of body and respiratory parameters were analyzed. Results The effectiveness rates in the experiment group and the control group were 93.8 % and 72.5 % respectively with significant difference （P 〈 0.05）. Short breath, rhinostegno- sis, cyanosis, lung rale and hospital stay in experiment group were much earlier than those in the control group （P 〈 0.05）. 24 and 48 hours after treatment, PCO2 greatly decreased and OI in- creased in comparison with the control group （ P 〈 0.05）. Conclusion Inhaled budesonide and ambroxol for neonatal pneumonia greatly reduce treatment duration and improve the clinical effect.